Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). (Q44718903)
scientific article
Language:
(P31) (Q13442814)
(P304) 299-305
(P433) 4
(P478) 2
(P577) Sunday, April 1, 2007
(P921) (Q181600)
(Q880)
(P1433) (Q2448056)
(P1476) "Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)." (language: en)
(P2093) Shirish M Gadgeel
John C Ruckdeschel
Elisabeth I Heath
Lance K Heilbrun
Raghu Venkatramanamoorthy
Antoinette Wozniak
other details
description scientific article

External Links